Geode Capital Management
ARQT icon

Geode Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Geode Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.2M Sell
2,982,446
-62,860
-2% -$1.46M ﹤0.01% 1365
2026
Q1 		$71.8M Buy
3,045,306
+291,999
+11% +$7.45M ﹤0.01% 1289
2025
Q4 		$80M Buy
2,753,307
+146,842
+6% +$3.76M ﹤0.01% 1220
2025
Q3 		$49.1M Buy
2,606,465
+23,898
+0.9% +$377K ﹤0.01% 1473
2025
Q2 		$36.2M Buy
2,582,567
+35,620
+1% +$499K ﹤0.01% 1607
2025
Q1 		$39.8M Buy
2,546,947
+74,217
+3% +$1.05M ﹤0.01% 1518
2024
Q4 		$34.5M Buy
2,472,730
+2,592
+0.1% +$28.4K ﹤0.01% 1661
2024
Q3 		$23M Buy
2,470,138
+48,868
+2% +$482K ﹤0.01% 1912
2024
Q2 		$22.5M Buy
2,421,270
+449,837
+23% +$4.07M ﹤0.01% 1868
2024
Q1 		$19.5M Buy
1,971,433
+227,844
+13% +$1.7M ﹤0.01% 1945
2023
Q4 		$5.63M Buy
1,743,589
+705,643
+68% +$1.92M ﹤0.01% 2645
2023
Q3 		$5.51M Buy
1,037,946
+100,499
+11% +$855K ﹤0.01% 2586
2023
Q2 		$8.93M Buy
937,447
+129,080
+16% +$1.43M ﹤0.01% 2351
2023
Q1 		$8.89M Buy
808,367
+29,223
+4% +$423K ﹤0.01% 2328
2022
Q4 		$11.5M Buy
779,144
+44,900
+6% +$784K ﹤0.01% 2164
2022
Q3 		$14M Buy
734,244
+165,578
+29% +$3.75M ﹤0.01% 1998
2022
Q2 		$12.1M Buy
568,666
+59,285
+12% +$1.22M ﹤0.01% 2123
2022
Q1 		$9.81M Buy
509,381
+20,037
+4% +$339K ﹤0.01% 2355
2021
Q4 		$10.1M Buy
489,344
+489
+0.1% +$9.73K ﹤0.01% 2441
2021
Q3 		$11.7M Buy
488,855
+13,888
+3% +$317K ﹤0.01% 2351
2021
Q2 		$13M Buy
474,967
+43,209
+10% +$1.22M ﹤0.01% 2282
2021
Q1 		$12.5M Buy
431,758
+93,606
+28% +$2.92M ﹤0.01% 2208
2020
Q4 		$9.51M Buy
338,152
+90,239
+36% +$2.21M ﹤0.01% 2215
2020
Q3 		$7.26M Buy
247,913
+95,651
+63% +$2.56M ﹤0.01% 2163
2020
Q2 		$4.6M Buy
152,262
+91,882
+152% +$2.66M ﹤0.01% 2384
2020
Q1 		$1.8M Buy
+60,380
New +$1.62M ﹤0.01% 2726

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management's ARQT Position: Q2 2026 in Review

Geode Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 2.1% in Q2 2026, selling an estimated $1.46M and leaving 2,982,446 shares worth $78.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1365.

Geode Capital Management first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $80M in Q4 2025. 249 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Geode Capital Management held 2,982,446 shares of Arcutis Biotherapeutics worth $78.2M as of Q2 2026.
  • Geode Capital Management sold 62,860 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.46M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1365 holding.
  • Geode Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Geode Capital Management's Arcutis Biotherapeutics position peaked at $80M in Q4 2025.
  • 249 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.